home / stock / humdf / humdf news
Hua Medicine Announces 2023 Interim Results SHANGHAI, CHINA, Aug 25, 2023 - (ACN Newswire) - -- First-in-class glucokinase activator (GKA) HuaTangNing (dorzagliatin) was approved in China in September 2022. Since the launch of commercial sales at the end of October 2022 to June 30, 2023, Hu...
Hua Medicine's Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China SHANGHAI, CHINA, Oct 10, 2022 - (ACN Newswire) - Hua Medicine (the "Company", HKEx Stock Code: 2552.HK) today announces that the New D...
Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022 SHANGHAI, CHINA, June 7, 2022 - (ACN Newswire) - Hua Medicine (the "Company", stock code: 2552.HK) today announces that several clinical find...
News, Short Squeeze, Breakout and More Instantly...
Hua Medicine Company Name:
HUMDF Stock Symbol:
OTCMKTS Market:
Hua Medicine Announces 2023 Interim Results SHANGHAI, CHINA, Aug 25, 2023 - (ACN Newswire) - -- First-in-class glucokinase activator (GKA) HuaTangNing (dorzagliatin) was approved in China in September 2022. Since the launch of commercial sales at the end of October 2022 to June 30, 2023, Hu...
Hua Medicine's Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China SHANGHAI, CHINA, Oct 10, 2022 - (ACN Newswire) - Hua Medicine (the "Company", HKEx Stock Code: 2552.HK) today announces that the New D...
Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022 SHANGHAI, CHINA, June 7, 2022 - (ACN Newswire) - Hua Medicine (the "Company", stock code: 2552.HK) today announces that several clinical find...